世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 抗体発見市場規模に関する世界的な調査および予測：抗体発見の段階別（ヒット生成、リード選定、リード最適化）、抗体発見手法別（ハイブリドーマ法、ファージディスプレイライブラリー法、トランスジェニック動物法、イーストディスプレイ法、単一細胞法、その他）、 抗体の性質（ヒト抗体、ヒト化抗体、キメラ抗体、マウス抗体）、抗体の種類（モノクローナル抗体、二重特異性抗体、抗体薬物複合体、免疫複合体、その他の抗体）、 治療領域（腫瘍学、自己免疫疾患、感染症、神経疾患、心血管疾患、その他）、エンドユーザー（製薬・バイオテクノロジー企業、CRO（医薬品開発受託機関）、学術・研究機関）、および2025年から2035年までの地域別予測Global Antibody Discovery Market Size Study and Forecast by Antibody Discovery Step (Hit Generation, Lead Selection and Lead Optimization), Antibody Discovery Method (Hybridoma-based, Phage Display Library, Transgenic Animal-based, Yeast Display-based, Single Cell-based and Other Methods), Nature of Antibody (Human Antibodies, Humanized Antibodies, Chimeric Antibodies and Murine Antibodies), Type of Antibody (Monoclonal Antibodies, Bispecific Antibodies, Antibody Drug Conjugates, Immunoconjugates and Other Antibodies), Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, Others), End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes), and Regional Forecasts 20252035 Market Definition, Recent Developments & Industry Trends The antibody discovery market encompasses technologies, platforms, and services involved in identifying, screening, and optimizing antibodi... もっと見る
出版社
Bizwit Research & Consulting LLP
ビズウィットリサーチ&コンサルティング 出版年月
2026年3月24日
電子版価格
納期
3-5営業日以内
ページ数
285
言語
英語
英語原文をAI翻訳して掲載しています。
サマリーMarket Definition, Recent Developments & Industry TrendsThe antibody discovery market encompasses technologies, platforms, and services involved in identifying, screening, and optimizing antibodies for therapeutic, diagnostic, and research applications. This market includes early-stage hit generation, lead selection and optimization processes, and diverse discovery methodologies such as hybridoma, phage display, transgenic animal-based systems, and single-cell sequencing technologies. Stakeholders span pharmaceutical and biotechnology companies, contract research organizations (CROs), academic laboratories, and technology platform providers specializing in biologics innovation. Over the past decade, antibody discovery has transitioned from conventional hybridoma-based approaches to highly automated, high-throughput, and AI-assisted platforms. Advances in next-generation sequencing, bioinformatics, and microfluidics have significantly reduced discovery timelines while improving antibody specificity and developability profiles. Rising demand for targeted biologics, the expansion of bispecific antibodies and antibody-drug conjugates (ADCs), and a growing emphasis on precision medicine have accelerated investment in advanced discovery platforms. As the biologics pipeline expands globally, antibody discovery is increasingly positioned as a strategic upstream capability critical to long-term value creation in the biopharmaceutical ecosystem. Key Findings of the Report - Market Size (2024): USD 1.78 billion - Estimated Market Size (2035): USD 6.38 billion - CAGR (2025-2035): 12.30% - Leading Regional Market: North America - Leading Segment: Monoclonal Antibodies under Type of Antibody Market Determinants Expanding Biologics Pipeline and Targeted Therapies The growing dominance of biologics in global drug pipelines is a primary growth driver. Antibodies represent a significant proportion of clinical-stage assets, particularly in oncology and immunology. As pharmaceutical companies prioritize targeted therapies with improved efficacy and safety profiles, robust discovery platforms become commercially indispensable, directly influencing pipeline productivity and time-to-market. Technological Advancements in Discovery Platforms High-throughput screening, single-cell sequencing, and AI-enabled epitope mapping are transforming discovery workflows. These technologies enhance hit identification accuracy and reduce attrition during downstream development. From a commercial perspective, faster and more predictive discovery platforms improve R&D return on investment and strengthen competitive differentiation. Rising Demand for Complex Antibody Formats The emergence of bispecific antibodies, ADCs, and immunoconjugates has introduced structural complexity requiring sophisticated discovery and optimization tools. Companies capable of generating high-affinity, developable candidates for multi-specific formats gain strategic advantage, as these therapies often command premium pricing and address unmet clinical needs. Strategic Outsourcing to CROs Pharmaceutical and biotechnology firms increasingly outsource early-stage discovery to specialized CROs to optimize costs and access advanced platforms. This structural shift enhances scalability within the ecosystem, enabling smaller biotech firms to access cutting-edge technologies without heavy capital expenditure. Regulatory and Developmental Complexity Stringent regulatory expectations around safety, immunogenicity, and manufacturability create barriers to entry and increase development costs. Discovery-stage optimization must anticipate downstream regulatory requirements, adding technical and financial complexity to early research phases. High Capital Intensity and Skill Requirements Establishing advanced antibody discovery infrastructure requires significant investment in automation systems, bioinformatics capabilities, and skilled scientific personnel. This may constrain smaller players and consolidate market share among technology leaders and established service providers. Opportunity Mapping Based on Market Trends AI-Integrated Antibody Discovery Platforms - Machine learning for antigen-antibody interaction prediction - In silico developability assessment The integration of artificial intelligence into discovery workflows offers substantial opportunity to reduce cycle times and improve candidate quality, attracting investment and strategic partnerships. Expansion in Oncology and Precision Medicine - Tumor-specific antigen targeting - Personalized antibody therapeutics Oncology remains the most lucrative therapeutic area, particularly for bispecifics and ADCs. Companies aligning discovery capabilities with precision oncology trends are well-positioned for sustained growth. Growth in Emerging Biotech Ecosystems - Asia Pacific biotech expansion - Government-funded translational research initiatives Emerging biotech hubs present opportunities for platform licensing, co-development agreements, and CRO service expansion. Development of Fully Human Antibodies - Reduced immunogenicity - Improved clinical success rates Human and humanized antibodies are increasingly preferred due to favorable safety profiles, creating premium demand for transgenic animal-based and single-cell-based technologies. Key Market Segments By Antibody Discovery Step: - Hit Generation - Lead Selection - Lead Optimization By Antibody Discovery Method: - Hybridoma-based - Phage Display Library - Transgenic Animal-based - Yeast Display-based - Single Cell-based - Other Methods By Nature of Antibody: - Human Antibodies - Humanized Antibodies - Chimeric Antibodies - Murine Antibodies By Type of Antibody: - Monoclonal Antibodies - Bispecific Antibodies - Antibody Drug Conjugates - Immunoconjugates - Other Antibodies By Therapeutic Area: - Oncology - Autoimmune Diseases - Infectious Diseases - Neurological Disorders - Cardiovascular Diseases - Others By End-user: - Pharmaceutical & Biotechnology Companies - Contract Research Organizations - Academic & Research Institutes Value-Creating Segments and Growth Pockets Monoclonal antibodies currently dominate revenue contribution due to their established regulatory pathway and extensive commercial track record. However, bispecific antibodies and antibody-drug conjugates are expected to register the fastest growth, driven by superior therapeutic potential and expanding clinical pipelines. Hybridoma-based methods retain historical significance, yet single cell-based and phage display technologies are anticipated to expand more rapidly owing to higher throughput and precision. In terms of antibody nature, human and humanized antibodies dominate and are projected to further consolidate share, while murine antibodies continue to decline due to immunogenicity concerns. Oncology leads among therapeutic areas, reflecting robust R&D funding and high unmet need. Meanwhile, autoimmune and neurological disorders represent emerging growth pockets as biologics penetrate chronic disease management. Among end-users, pharmaceutical and biotechnology companies command the largest share, while CROs are expected to grow at a faster pace due to outsourcing trends. Regional Market Assessment North America North America leads the global market, supported by strong biologics R&D infrastructure, substantial venture capital funding, and the presence of leading biopharmaceutical companies. Regulatory clarity and advanced academic research ecosystems further reinforce innovation. Europe Europe benefits from strong translational research programs and public-private partnerships in biologics development. Emphasis on biosimilar development and advanced therapy medicinal products supports steady expansion of discovery activities. Asia Pacific Asia Pacific is projected to witness the fastest growth, driven by expanding biotechnology sectors in China, India, South Korea, and Japan. Government funding, growing CRO capabilities, and cost-efficient research environments enhance regional competitiveness. LAMEA The LAMEA region demonstrates gradual growth, supported by increasing healthcare investment and strategic collaborations with global biopharma players. Although infrastructure constraints persist, selective investment in research capabilities is creating long-term potential. Recent Developments - February 2024: A biotechnology firm launched an AI-driven antibody discovery platform integrating single-cell sequencing, reducing lead identification timelines and strengthening competitive differentiation. - October 2023: A major pharmaceutical company entered a multi-year partnership with a CRO specializing in phage display technologies, reflecting increasing outsourcing of early-stage discovery. - June 2024: Expansion of a transgenic animal-based antibody discovery facility in Asia Pacific, aimed at supporting rising regional biologics pipelines and improving turnaround times. Critical Business Questions Addressed - What is the revenue outlook for the antibody discovery market through 2035- The report quantifies growth trajectories and identifies structural demand drivers across discovery steps and antibody formats. - Which discovery methods offer the strongest competitive advantage- It evaluates technological differentiation, scalability, and cost efficiency across platform types. - How should companies prioritize investment across therapeutic areas- The analysis compares pipeline intensity, funding trends, and commercial potential by indication. - What role will outsourcing play in reshaping the competitive landscape- The report assesses CRO growth dynamics and partnership-driven value creation. - Where are the fastest-growing geographic opportunities- It examines regional innovation ecosystems and investment flows influencing market expansion. Beyond the Forecast The antibody discovery market is entering a phase defined by platform sophistication, digital integration, and biologics complexity. Competitive advantage will increasingly hinge on predictive analytics, automation, and the ability to generate highly specific, low-immunogenicity candidates. As therapeutic modalities diversify and precision medicine advances, discovery capabilities will become central to strategic differentiation within the biopharmaceutical value chain. Organizations that combine technological agility with collaborative ecosystem strategies will shape the next decade of biologics innovation. 目次Table of ContentsChapter 1. Global Antibody Discovery Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Antibody Discovery Market Forces Analysis 3.1. Market Forces Shaping The Global Antibody Discovery Market (2024-2035) 3.2. Drivers 3.2.1. Expanding Biologics Pipeline and Targeted Therapies 3.2.2. Technological Advancements in Discovery Platforms 3.2.3. Rising Demand for Complex Antibody Formats 3.2.4. Strategic Outsourcing to CROs 3.3. Restraints 3.3.1. Regulatory and Developmental Complexity 3.3.2. High Capital Intensity and Skill Requirements 3.4. Opportunities 3.4.1. AI-Integrated Antibody Discovery Platforms 3.4.2. Expansion in Oncology and Precision Medicine Chapter 4. Global Antibody Discovery Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Antibody Discovery Market Size & Forecasts by Antibody Discovery Step 2025-2035 6.1. Market Overview 6.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 6.3. Hit Generation 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Lead Selection 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Lead Optimization 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Antibody Discovery Market Size & Forecasts by Antibody Discovery Method 2025-2035 7.1. Market Overview 7.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 7.3. Hybridoma-based 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Phage Display Library 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 7.5. Transgenic Animal-based 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.5.2. Market size analysis, by region, 2025-2035 7.6. Yeast Display-based 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.6.2. Market size analysis, by region, 2025-2035 7.7. Single Cell-based 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.7.2. Market size analysis, by region, 2025-2035 7.8. Other Methods 7.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.8.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Antibody Discovery Market Size & Forecasts by Nature of Antibody 2025-2035 8.1. Market Overview 8.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 8.3. Human Antibodies 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. Humanized Antibodies 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 8.5. Chimeric Antibodies 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.5.2. Market size analysis, by region, 2025-2035 8.6. Murine Antibodies 8.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.6.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Antibody Discovery Market Size & Forecasts by Type of Antibody 2025-2035 9.1. Market Overview 9.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 9.3. Monoclonal Antibodies 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.3.2. Market size analysis, by region, 2025-2035 9.4. Bispecific Antibodies 9.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.4.2. Market size analysis, by region, 2025-2035 9.5. Antibody Drug Conjugates 9.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.5.2. Market size analysis, by region, 2025-2035 9.6. Immunoconjugates 9.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.6.2. Market size analysis, by region, 2025-2035 9.7. Other Antibodies 9.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.7.2. Market size analysis, by region, 2025-2035 Chapter 10. Global Antibody Discovery Market Size & Forecasts by Therapeutic Area 2025-2035 10.1. Market Overview 10.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 10.3. Oncology 10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.3.2. Market size analysis, by region, 2025-2035 10.4. Autoimmune Diseases 10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.4.2. Market size analysis, by region, 2025-2035 10.5. Infectious Diseases 10.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.5.2. Market size analysis, by region, 2025-2035 10.6. Neurological Disorders 10.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.6.2. Market size analysis, by region, 2025-2035 10.7. Cardiovascular Diseases 10.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.7.2. Market size analysis, by region, 2025-2035 10.8. Others 10.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.8.2. Market size analysis, by region, 2025-2035 Chapter 11. Global Antibody Discovery Market Size & Forecasts by End User 2025-2035 11.1. Market Overview 11.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 11.3. Pharmaceutical & Biotechnology Companies 11.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.3.2. Market size analysis, by region, 2025-2035 11.4. Contract Research Organizations 11.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.4.2. Market size analysis, by region, 2025-2035 11.5. Academic & Research Institutes 11.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.5.2. Market size analysis, by region, 2025-2035 Chapter 12. Global Antibody Discovery Market Size & Forecasts by Region 2025–2035 12.1. Growth Antibody Discovery Market, Regional Market Snapshot 12.2. Top Leading & Emerging Countries 12.3. North America Antibody Discovery Market 12.3.1. U.S. Antibody Discovery Market 12.3.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.3.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.3.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.3.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.3.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.3.1.6. End User breakdown size & forecasts, 2025-2035 12.3.2. Canada Antibody Discovery Market 12.3.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.3.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.3.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.3.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.3.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.3.2.6. End User breakdown size & forecasts, 2025-2035 12.4. Europe Antibody Discovery Market 12.4.1. UK Antibody Discovery Market 12.4.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.1.6. End User breakdown size & forecasts, 2025-2035 12.4.2. Germany Antibody Discovery Market 12.4.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.2.6. End User breakdown size & forecasts, 2025-2035 12.4.3. France Antibody Discovery Market 12.4.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.3.6. End User breakdown size & forecasts, 2025-2035 12.4.4. Spain Antibody Discovery Market 12.4.4.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.4.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.4.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.4.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.4.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.4.6. End User breakdown size & forecasts, 2025-2035 12.4.5. Italy Antibody Discovery Market 12.4.5.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.5.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.5.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.5.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.5.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.5.6. End User breakdown size & forecasts, 2025-2035 12.4.6. Rest of Europe Antibody Discovery Market 12.4.6.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.6.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.6.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.6.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.6.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.6.6. End User breakdown size & forecasts, 2025-2035 12.5. Asia Pacific Antibody Discovery Market 12.5.1. China Antibody Discovery Market 12.5.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.1.6. End User breakdown size & forecasts, 2025-2035 12.5.2. India Antibody Discovery Market 12.5.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.2.6. End User breakdown size & forecasts, 2025-2035 12.5.3. Japan Antibody Discovery Market 12.5.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.3.6. End User breakdown size & forecasts, 2025-2035 12.5.4. Australia Antibody Discovery Market 12.5.4.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.4.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.4.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.4.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.4.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.4.6. End User breakdown size & forecasts, 2025-2035 12.5.5. South Korea Antibody Discovery Market 12.5.5.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.5.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.5.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.5.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.5.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.5.6. End User breakdown size & forecasts, 2025-2035 12.5.6. Rest of APAC Antibody Discovery Market 12.5.6.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.6.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.6.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.6.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.6.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.6.6. End User breakdown size & forecasts, 2025-2035 12.6. Latin America Antibody Discovery Market 12.6.1. Brazil Antibody Discovery Market 12.6.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.6.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.6.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.6.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.6.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.6.1.6. End User breakdown size & forecasts, 2025-2035 12.6.2. Mexico Antibody Discovery Market 12.6.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.6.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.6.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.6.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.6.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.6.2.6. End User breakdown size & forecasts, 2025-2035 12.7. Middle East and Africa Antibody Discovery Market 12.7.1. UAE Antibody Discovery Market 12.7.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.1.6. End User breakdown size & forecasts, 2025-2035 12.7.2. Saudi Arabia (KSA) Antibody Discovery Market 12.7.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.2.6. End User breakdown size & forecasts, 2025-2035 12.7.3. South Africa Antibody Discovery Market 12.7.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.3.6. End User breakdown size & forecasts, 2025-2035 Chapter 13. Competitive Intelligence 13.1. Top Market Strategies 13.2. Ablexis 13.2.1. Company Overview 13.2.2. Key Executives 13.2.3. Company Snapshot 13.2.4. Financial Performance (Subject to Data Availability) 13.2.5. Product/Services Port 13.2.6. Recent Development 13.2.7. Market Strategies 13.2.8. SWOT Analysis 13.3. Abwiz Bio 13.4. Abzena 13.5. Aragen Life Sciences 13.6. BIOTEM 13.7. ChemPartner 13.8. Creative Biolabs 13.9. DetaiBio 13.10. FairJourney Biologics 13.11. Fusion Antibodies 13.12. Genmab 13.13. Harbour BioMed 13.14. Immunome 13.15. ImmunoPrecise Antibodies 13.16. Integral Molecular 13.17. Isogenica 13.18. ProteoGenix 13.19. Syd Labs 図表リストList of TablesTable 1. Global Antibody Discovery Market, Report Scope Table 2. Global Antibody Discovery Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 9. Canada Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 10. UK Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 11. Germany Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 12. France Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 13. Spain Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 14. Italy Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 16. China Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 17. India Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 18. Japan Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 19. Australia Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Antibody Discovery Market Estimates & Forecasts, 2024–2035 ………….
SummaryMarket Definition, Recent Developments & Industry TrendsThe antibody discovery market encompasses technologies, platforms, and services involved in identifying, screening, and optimizing antibodies for therapeutic, diagnostic, and research applications. This market includes early-stage hit generation, lead selection and optimization processes, and diverse discovery methodologies such as hybridoma, phage display, transgenic animal-based systems, and single-cell sequencing technologies. Stakeholders span pharmaceutical and biotechnology companies, contract research organizations (CROs), academic laboratories, and technology platform providers specializing in biologics innovation. Over the past decade, antibody discovery has transitioned from conventional hybridoma-based approaches to highly automated, high-throughput, and AI-assisted platforms. Advances in next-generation sequencing, bioinformatics, and microfluidics have significantly reduced discovery timelines while improving antibody specificity and developability profiles. Rising demand for targeted biologics, the expansion of bispecific antibodies and antibody-drug conjugates (ADCs), and a growing emphasis on precision medicine have accelerated investment in advanced discovery platforms. As the biologics pipeline expands globally, antibody discovery is increasingly positioned as a strategic upstream capability critical to long-term value creation in the biopharmaceutical ecosystem. Key Findings of the Report - Market Size (2024): USD 1.78 billion - Estimated Market Size (2035): USD 6.38 billion - CAGR (2025-2035): 12.30% - Leading Regional Market: North America - Leading Segment: Monoclonal Antibodies under Type of Antibody Market Determinants Expanding Biologics Pipeline and Targeted Therapies The growing dominance of biologics in global drug pipelines is a primary growth driver. Antibodies represent a significant proportion of clinical-stage assets, particularly in oncology and immunology. As pharmaceutical companies prioritize targeted therapies with improved efficacy and safety profiles, robust discovery platforms become commercially indispensable, directly influencing pipeline productivity and time-to-market. Technological Advancements in Discovery Platforms High-throughput screening, single-cell sequencing, and AI-enabled epitope mapping are transforming discovery workflows. These technologies enhance hit identification accuracy and reduce attrition during downstream development. From a commercial perspective, faster and more predictive discovery platforms improve R&D return on investment and strengthen competitive differentiation. Rising Demand for Complex Antibody Formats The emergence of bispecific antibodies, ADCs, and immunoconjugates has introduced structural complexity requiring sophisticated discovery and optimization tools. Companies capable of generating high-affinity, developable candidates for multi-specific formats gain strategic advantage, as these therapies often command premium pricing and address unmet clinical needs. Strategic Outsourcing to CROs Pharmaceutical and biotechnology firms increasingly outsource early-stage discovery to specialized CROs to optimize costs and access advanced platforms. This structural shift enhances scalability within the ecosystem, enabling smaller biotech firms to access cutting-edge technologies without heavy capital expenditure. Regulatory and Developmental Complexity Stringent regulatory expectations around safety, immunogenicity, and manufacturability create barriers to entry and increase development costs. Discovery-stage optimization must anticipate downstream regulatory requirements, adding technical and financial complexity to early research phases. High Capital Intensity and Skill Requirements Establishing advanced antibody discovery infrastructure requires significant investment in automation systems, bioinformatics capabilities, and skilled scientific personnel. This may constrain smaller players and consolidate market share among technology leaders and established service providers. Opportunity Mapping Based on Market Trends AI-Integrated Antibody Discovery Platforms - Machine learning for antigen-antibody interaction prediction - In silico developability assessment The integration of artificial intelligence into discovery workflows offers substantial opportunity to reduce cycle times and improve candidate quality, attracting investment and strategic partnerships. Expansion in Oncology and Precision Medicine - Tumor-specific antigen targeting - Personalized antibody therapeutics Oncology remains the most lucrative therapeutic area, particularly for bispecifics and ADCs. Companies aligning discovery capabilities with precision oncology trends are well-positioned for sustained growth. Growth in Emerging Biotech Ecosystems - Asia Pacific biotech expansion - Government-funded translational research initiatives Emerging biotech hubs present opportunities for platform licensing, co-development agreements, and CRO service expansion. Development of Fully Human Antibodies - Reduced immunogenicity - Improved clinical success rates Human and humanized antibodies are increasingly preferred due to favorable safety profiles, creating premium demand for transgenic animal-based and single-cell-based technologies. Key Market Segments By Antibody Discovery Step: - Hit Generation - Lead Selection - Lead Optimization By Antibody Discovery Method: - Hybridoma-based - Phage Display Library - Transgenic Animal-based - Yeast Display-based - Single Cell-based - Other Methods By Nature of Antibody: - Human Antibodies - Humanized Antibodies - Chimeric Antibodies - Murine Antibodies By Type of Antibody: - Monoclonal Antibodies - Bispecific Antibodies - Antibody Drug Conjugates - Immunoconjugates - Other Antibodies By Therapeutic Area: - Oncology - Autoimmune Diseases - Infectious Diseases - Neurological Disorders - Cardiovascular Diseases - Others By End-user: - Pharmaceutical & Biotechnology Companies - Contract Research Organizations - Academic & Research Institutes Value-Creating Segments and Growth Pockets Monoclonal antibodies currently dominate revenue contribution due to their established regulatory pathway and extensive commercial track record. However, bispecific antibodies and antibody-drug conjugates are expected to register the fastest growth, driven by superior therapeutic potential and expanding clinical pipelines. Hybridoma-based methods retain historical significance, yet single cell-based and phage display technologies are anticipated to expand more rapidly owing to higher throughput and precision. In terms of antibody nature, human and humanized antibodies dominate and are projected to further consolidate share, while murine antibodies continue to decline due to immunogenicity concerns. Oncology leads among therapeutic areas, reflecting robust R&D funding and high unmet need. Meanwhile, autoimmune and neurological disorders represent emerging growth pockets as biologics penetrate chronic disease management. Among end-users, pharmaceutical and biotechnology companies command the largest share, while CROs are expected to grow at a faster pace due to outsourcing trends. Regional Market Assessment North America North America leads the global market, supported by strong biologics R&D infrastructure, substantial venture capital funding, and the presence of leading biopharmaceutical companies. Regulatory clarity and advanced academic research ecosystems further reinforce innovation. Europe Europe benefits from strong translational research programs and public-private partnerships in biologics development. Emphasis on biosimilar development and advanced therapy medicinal products supports steady expansion of discovery activities. Asia Pacific Asia Pacific is projected to witness the fastest growth, driven by expanding biotechnology sectors in China, India, South Korea, and Japan. Government funding, growing CRO capabilities, and cost-efficient research environments enhance regional competitiveness. LAMEA The LAMEA region demonstrates gradual growth, supported by increasing healthcare investment and strategic collaborations with global biopharma players. Although infrastructure constraints persist, selective investment in research capabilities is creating long-term potential. Recent Developments - February 2024: A biotechnology firm launched an AI-driven antibody discovery platform integrating single-cell sequencing, reducing lead identification timelines and strengthening competitive differentiation. - October 2023: A major pharmaceutical company entered a multi-year partnership with a CRO specializing in phage display technologies, reflecting increasing outsourcing of early-stage discovery. - June 2024: Expansion of a transgenic animal-based antibody discovery facility in Asia Pacific, aimed at supporting rising regional biologics pipelines and improving turnaround times. Critical Business Questions Addressed - What is the revenue outlook for the antibody discovery market through 2035- The report quantifies growth trajectories and identifies structural demand drivers across discovery steps and antibody formats. - Which discovery methods offer the strongest competitive advantage- It evaluates technological differentiation, scalability, and cost efficiency across platform types. - How should companies prioritize investment across therapeutic areas- The analysis compares pipeline intensity, funding trends, and commercial potential by indication. - What role will outsourcing play in reshaping the competitive landscape- The report assesses CRO growth dynamics and partnership-driven value creation. - Where are the fastest-growing geographic opportunities- It examines regional innovation ecosystems and investment flows influencing market expansion. Beyond the Forecast The antibody discovery market is entering a phase defined by platform sophistication, digital integration, and biologics complexity. Competitive advantage will increasingly hinge on predictive analytics, automation, and the ability to generate highly specific, low-immunogenicity candidates. As therapeutic modalities diversify and precision medicine advances, discovery capabilities will become central to strategic differentiation within the biopharmaceutical value chain. Organizations that combine technological agility with collaborative ecosystem strategies will shape the next decade of biologics innovation. Table of ContentsTable of ContentsChapter 1. Global Antibody Discovery Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Antibody Discovery Market Forces Analysis 3.1. Market Forces Shaping The Global Antibody Discovery Market (2024-2035) 3.2. Drivers 3.2.1. Expanding Biologics Pipeline and Targeted Therapies 3.2.2. Technological Advancements in Discovery Platforms 3.2.3. Rising Demand for Complex Antibody Formats 3.2.4. Strategic Outsourcing to CROs 3.3. Restraints 3.3.1. Regulatory and Developmental Complexity 3.3.2. High Capital Intensity and Skill Requirements 3.4. Opportunities 3.4.1. AI-Integrated Antibody Discovery Platforms 3.4.2. Expansion in Oncology and Precision Medicine Chapter 4. Global Antibody Discovery Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Antibody Discovery Market Size & Forecasts by Antibody Discovery Step 2025-2035 6.1. Market Overview 6.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 6.3. Hit Generation 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Lead Selection 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Lead Optimization 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Antibody Discovery Market Size & Forecasts by Antibody Discovery Method 2025-2035 7.1. Market Overview 7.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 7.3. Hybridoma-based 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Phage Display Library 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 7.5. Transgenic Animal-based 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.5.2. Market size analysis, by region, 2025-2035 7.6. Yeast Display-based 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.6.2. Market size analysis, by region, 2025-2035 7.7. Single Cell-based 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.7.2. Market size analysis, by region, 2025-2035 7.8. Other Methods 7.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.8.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Antibody Discovery Market Size & Forecasts by Nature of Antibody 2025-2035 8.1. Market Overview 8.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 8.3. Human Antibodies 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. Humanized Antibodies 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 8.5. Chimeric Antibodies 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.5.2. Market size analysis, by region, 2025-2035 8.6. Murine Antibodies 8.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.6.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Antibody Discovery Market Size & Forecasts by Type of Antibody 2025-2035 9.1. Market Overview 9.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 9.3. Monoclonal Antibodies 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.3.2. Market size analysis, by region, 2025-2035 9.4. Bispecific Antibodies 9.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.4.2. Market size analysis, by region, 2025-2035 9.5. Antibody Drug Conjugates 9.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.5.2. Market size analysis, by region, 2025-2035 9.6. Immunoconjugates 9.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.6.2. Market size analysis, by region, 2025-2035 9.7. Other Antibodies 9.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.7.2. Market size analysis, by region, 2025-2035 Chapter 10. Global Antibody Discovery Market Size & Forecasts by Therapeutic Area 2025-2035 10.1. Market Overview 10.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 10.3. Oncology 10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.3.2. Market size analysis, by region, 2025-2035 10.4. Autoimmune Diseases 10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.4.2. Market size analysis, by region, 2025-2035 10.5. Infectious Diseases 10.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.5.2. Market size analysis, by region, 2025-2035 10.6. Neurological Disorders 10.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.6.2. Market size analysis, by region, 2025-2035 10.7. Cardiovascular Diseases 10.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.7.2. Market size analysis, by region, 2025-2035 10.8. Others 10.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.8.2. Market size analysis, by region, 2025-2035 Chapter 11. Global Antibody Discovery Market Size & Forecasts by End User 2025-2035 11.1. Market Overview 11.2. Global Antibody Discovery Market Performance - Potential Analysis (2025) 11.3. Pharmaceutical & Biotechnology Companies 11.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.3.2. Market size analysis, by region, 2025-2035 11.4. Contract Research Organizations 11.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.4.2. Market size analysis, by region, 2025-2035 11.5. Academic & Research Institutes 11.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 11.5.2. Market size analysis, by region, 2025-2035 Chapter 12. Global Antibody Discovery Market Size & Forecasts by Region 2025–2035 12.1. Growth Antibody Discovery Market, Regional Market Snapshot 12.2. Top Leading & Emerging Countries 12.3. North America Antibody Discovery Market 12.3.1. U.S. Antibody Discovery Market 12.3.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.3.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.3.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.3.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.3.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.3.1.6. End User breakdown size & forecasts, 2025-2035 12.3.2. Canada Antibody Discovery Market 12.3.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.3.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.3.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.3.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.3.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.3.2.6. End User breakdown size & forecasts, 2025-2035 12.4. Europe Antibody Discovery Market 12.4.1. UK Antibody Discovery Market 12.4.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.1.6. End User breakdown size & forecasts, 2025-2035 12.4.2. Germany Antibody Discovery Market 12.4.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.2.6. End User breakdown size & forecasts, 2025-2035 12.4.3. France Antibody Discovery Market 12.4.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.3.6. End User breakdown size & forecasts, 2025-2035 12.4.4. Spain Antibody Discovery Market 12.4.4.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.4.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.4.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.4.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.4.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.4.6. End User breakdown size & forecasts, 2025-2035 12.4.5. Italy Antibody Discovery Market 12.4.5.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.5.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.5.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.5.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.5.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.5.6. End User breakdown size & forecasts, 2025-2035 12.4.6. Rest of Europe Antibody Discovery Market 12.4.6.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.4.6.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.4.6.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.4.6.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.4.6.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.4.6.6. End User breakdown size & forecasts, 2025-2035 12.5. Asia Pacific Antibody Discovery Market 12.5.1. China Antibody Discovery Market 12.5.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.1.6. End User breakdown size & forecasts, 2025-2035 12.5.2. India Antibody Discovery Market 12.5.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.2.6. End User breakdown size & forecasts, 2025-2035 12.5.3. Japan Antibody Discovery Market 12.5.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.3.6. End User breakdown size & forecasts, 2025-2035 12.5.4. Australia Antibody Discovery Market 12.5.4.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.4.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.4.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.4.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.4.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.4.6. End User breakdown size & forecasts, 2025-2035 12.5.5. South Korea Antibody Discovery Market 12.5.5.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.5.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.5.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.5.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.5.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.5.6. End User breakdown size & forecasts, 2025-2035 12.5.6. Rest of APAC Antibody Discovery Market 12.5.6.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.5.6.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.5.6.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.5.6.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.5.6.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.5.6.6. End User breakdown size & forecasts, 2025-2035 12.6. Latin America Antibody Discovery Market 12.6.1. Brazil Antibody Discovery Market 12.6.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.6.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.6.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.6.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.6.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.6.1.6. End User breakdown size & forecasts, 2025-2035 12.6.2. Mexico Antibody Discovery Market 12.6.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.6.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.6.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.6.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.6.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.6.2.6. End User breakdown size & forecasts, 2025-2035 12.7. Middle East and Africa Antibody Discovery Market 12.7.1. UAE Antibody Discovery Market 12.7.1.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.1.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.1.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.1.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.1.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.1.6. End User breakdown size & forecasts, 2025-2035 12.7.2. Saudi Arabia (KSA) Antibody Discovery Market 12.7.2.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.2.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.2.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.2.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.2.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.2.6. End User breakdown size & forecasts, 2025-2035 12.7.3. South Africa Antibody Discovery Market 12.7.3.1. Antibody Discovery Step breakdown size & forecasts, 2025-2035 12.7.3.2. Antibody Discovery Method breakdown size & forecasts, 2025-2035 12.7.3.3. Nature of Antibody breakdown size & forecasts, 2025-2035 12.7.3.4. Type of Antibody breakdown size & forecasts, 2025-2035 12.7.3.5. Therapeutic Area breakdown size & forecasts, 2025-2035 12.7.3.6. End User breakdown size & forecasts, 2025-2035 Chapter 13. Competitive Intelligence 13.1. Top Market Strategies 13.2. Ablexis 13.2.1. Company Overview 13.2.2. Key Executives 13.2.3. Company Snapshot 13.2.4. Financial Performance (Subject to Data Availability) 13.2.5. Product/Services Port 13.2.6. Recent Development 13.2.7. Market Strategies 13.2.8. SWOT Analysis 13.3. Abwiz Bio 13.4. Abzena 13.5. Aragen Life Sciences 13.6. BIOTEM 13.7. ChemPartner 13.8. Creative Biolabs 13.9. DetaiBio 13.10. FairJourney Biologics 13.11. Fusion Antibodies 13.12. Genmab 13.13. Harbour BioMed 13.14. Immunome 13.15. ImmunoPrecise Antibodies 13.16. Integral Molecular 13.17. Isogenica 13.18. ProteoGenix 13.19. Syd Labs List of Tables/GraphsList of TablesTable 1. Global Antibody Discovery Market, Report Scope Table 2. Global Antibody Discovery Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Antibody Discovery Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 9. Canada Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 10. UK Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 11. Germany Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 12. France Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 13. Spain Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 14. Italy Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 16. China Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 17. India Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 18. Japan Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 19. Australia Antibody Discovery Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Antibody Discovery Market Estimates & Forecasts, 2024–2035 ………….
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
Bizwit Research & Consulting LLP社の 医療・ライフサイエンス分野 での最新刊レポート
本レポートと同じKEY WORD（antibody）の最新刊レポート
関連レポート（キーワード「免疫」）
よくあるご質問Bizwit Research & Consulting LLP社はどのような調査会社ですか?Bizwit Research & Consulting (Bizwit Research & Consulting LLP)は世界の多様なマクロおよびマイクロ経済の動向を継続的に調査しています。 ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
